Back to Search

STEVEN LIMENTANI, MD

MD

Internal Medicine Physician

NPI: 1861409369Individual

Specialties, Licenses & Credentials

Hematology & Oncology Physician

Internal Medicine — Hematology & Oncology

Code: 207RH0003X

9500985(NC)
Medical Oncology Physician

Internal Medicine — Medical Oncology

Code: 207RX0202X

9500985(NC)
Hematology (Internal Medicine) Physician

Internal Medicine — Hematology

Code: 207RH0000X

9500985(NC)
Internal Medicine PhysicianPrimary

Internal Medicine

Code: 207R00000X

9500985(NC)

Research & Publications (20)

Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy.
PMID 18381372·Ann Oncol·2008
3-trial
Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer.
PMID 17296975·J Clin Oncol·2007
8-other
Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer.
PMID 16595034·Clin Breast Cancer·2006
3-trial
A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme.
PMID 15937647·J Neurooncol·2005
3-trial
Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS).
PMID 18781341·Support Care Cancer·2009
8-other
Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
PMID 19597027·J Clin Oncol·2009
3-trial
Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer.
PMID 18166839·J Thorac Oncol·2008
3-trial
Long-term follow-up of a phase I/II trial of dose escalating three-dimensional conformal thoracic radiation therapy with induction and concurrent carboplatin and paclitaxel in unresectable stage IIIA/B non-small cell lung cancer.
PMID 18978563·J Thorac Oncol·2008
3-trial
Inclusive K(S);(0)K(S);(0) resonance production in ep collisions at HERA.
PMID 18851276·Phys Rev Lett·2008
8-other
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
PMID 18783399·Br J Haematol·2008
3-trial
Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study.
PMID 16868545·Br J Cancer·2006
3-trial
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.
PMID 17075122·J Clin Oncol·2006
3-trial
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
PMID 16754936·J Clin Oncol·2006
3-trial
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
PMID 16206291·Cancer·2005
3-trial
Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer.
PMID 15905305·Ann Oncol·2005
3-trial
Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial.
PMID 15514375·J Clin Oncol·2004
3-trial
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
PMID 15461622·Br J Haematol·2004
3-trial
Recurrent primary fibrosarcoma of the brain treated with the GliaSite brachytherapy system: case report.
PMID 14670686·Surg Neurol·2003
5-case
A phase 2 study of bortezomib in relapsed, refractory myeloma.
PMID 12826635·N Engl J Med·2003
3-trial
Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial.
PMID 11571735·Cancer·2001
3-trial

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
21 HOSPITAL DR, 2ND FLOOR
ASHEVILLE, NC 28801

Location

Practice Location

21 HOSPITAL DR, ASHEVILLE, NC
(828) 213-2500

Quick Facts

NPI
1861409369
Entity Type
Individual
Gender
Male
Medicare
Not confirmed
Specialties
4
Locations
1
Publications
20

Are you this provider?

Claim Your Profile